Position in ANNX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$438,618
+$280,062 QoQ
Shares Held
79,173
+150.7% QoQ
Ownership
0.040%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 18.343374635292335.ToString("F0")%
Shared 0.ToString("F0")%
None 81.65662536470766.ToString("F0")%
Common Shares in ANNX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026CAPTRUST FINANCIAL ADVISORS holds $130,226,430 across 94 Biotechnology names. ANNX ranks #34 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
38,502 | $29,748,185 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
32,092 | $14,330,361 | |
| 3 | EXEL |
Exelixis, Inc.
|
312,296 | $13,394,375 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
121,088 | $7,825,917 | |
| 5 | CELC |
Celcuity Inc.
|
61,068 | $6,970,301 | |
| 6 | RPRX |
Royalty Pharma plc
|
143,760 | $6,896,167 | |
| 7 | LGND |
Ligand Pharmaceuticals Inc
|
29,900 | $5,969,535 | |
| 8 | INCY |
Incyte Corp
|
53,555 | $5,040,596 |
All Filings in ANNX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $438,618 | 79,173 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $158,556 | 31,585 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||